Scinai Immunotherapeutics Ltd.
- Capitalización de mercado
- $1.12M
- Volumen
- 2.73M
- Próxima fecha de resultados
- Nov 9, 2015
Scinai Immunotherapeutics Ltd. (SCNI): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $460.0K | n/a | +123.30% |
| EPS | -$240,00 | -$178,00 | -8375.86% |
Métricas
- Precio de compra
- 1.41
- Ingresos (TTM)
- 1.49M
- Beneficio neto (TTM)
- -2.6M
- 2.08
- 28.07
- 0.06
- n/a
- P/B (TTM)
- 0.15
- P/S (TTM)
- 0.76
- Fecha de resultados
- Nov 9, 2015
- Precio de venta
- 1.98
- Volumen
- 2,730,471
- Volumen medio (20D)
- 148,227
- Abierto
- 1.68
- Anterior Cerrar
- 1.67
- Rango del día
- 1.65 - 1.78
- Rango de 52 semanas
- 1.60 - 16.40
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Scinai Immunotherapeutics Ltd.
Ver perfil →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.